United States Patent 6,716,416: Scope, Claims, and US Patent Landscape
US Patent 6,716,416 is centered on condensation aerosol delivery of antipsychotic small molecules, with tight control of degradation and particle aerodynamic size. The patent is claim-built around (1) aerosol generation by volatilization and condensation, (2) quantified limits on degradation products, and (3) MMAD (mass median aerodynamic diameter) thresholds below 3 microns (with dependent claims tightening further). The scope is broad across multiple antipsychotics, but it is structurally constrained by the aerosol formation mechanism and specific aerosol/product quality parameters.
What does the patent claim cover at the highest level?
The independent claim set comprises:
-
Composition claims (Claims 1-6): a composition for delivering an antipsychotic compound, defined by aerosol formation method plus quantitative product quality:
- Condensation aerosol particles made by:
- volatilizing the antipsychotic to form heated vapor
- condensing to form aerosol particles
- Less than 5% compound degradation products
- Aerosol MMAD < 3 microns
- Dependent claims narrow the degradation profile and the mass fraction of parent compound, and tighten MMAD to < 2 microns.
-
Method claims (Claims 7-13): a method of producing the antipsychotic compound in aerosol form, defined by:
- volatilizing the selected antipsychotic
- passing air through the heated vapor during volatilization to form aerosol particles
- again requiring:
- < 5% degradation products
- MMAD < 3 microns
- Dependent claims add:
- aerosol formation rate > 0.5 mg/sec (Claim 8)
- volatilizing includes heating a coating on a solid support with surface texture of metal foil (Claim 9)
- tighter degradation thresholds and parent mass fractions
- tighter MMAD to < 2 microns
The claims are drafted to be enforceable as both product (composition) and process (method) protections, with the enforceable “hooks” being:
- Condensation aerosol formation from heated vapor
- Quantitative degradation limits
- Aerodynamic size limits (MMAD)
What is the core claim limitation on aerosol formation and product quality?
Independent claim logic (composition)
Claim 1 is the anchor and requires all of the following:
- A condensation aerosol formed by:
- volatilizing an antipsychotic compound under conditions effective to produce heated vapor
- condensing heated vapor to form condensation aerosol particles
- Particle quality:
- particles characterized by < 5% compound degradation products
- Particle size:
Independent claim logic (composition with explicit list)
Claim 2 repeats Claim 1 but restricts the antipsychotic to a defined list that includes:
- olanzapine
- trifluoperazine
- haloperidol
- loxapine
- risperidone
- clozapine
- quetiapine
- promazine
- thiothixene
- chlorpromazine
- droperidol
- prochlorperazine
- fluphenazine
It still requires < 5% degradation products and MMAD < 3 microns.
Independent claim logic (method)
Claim 7 requires:
- volatilizing an antipsychotic (from the same style list, including the same set plus some)
- passing air through the heated vapor during volatilization to form aerosol particles
- < 5% degradation products
- MMAD < 3 microns
Claim 7 also ties “method” to the same functional product quality constraints.
Which antipsychotics fall within the asserted claim scope?
Across Claims 2-6 (composition) and Claims 7-13 (method), the antipsychotic coverage includes the following recurring list.
Composition (Claims 2-6)
Claim 2 list (the broad composition list):
- olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine, fluphenazine
Dependent claims narrow degradation targets (Claim 3) and parent mass fraction targets (Claims 4, 6, 5/6 combination), but they remain within subsets of the Claim 2 list.
Method (Claims 7-13)
Claim 7 list includes:
- olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, fluphenazine
Dependent claims (Claims 10-13) again narrow to subsets consistent with the claims’ internal spelling, including:
- degradation products limits for “olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, or chlorpromazine” (Claim 10)
- parent mass fraction targets for “olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, chlorpromazine, prochlorperazine, or fluphenazine” (Claim 11/13)
What are the quantified quality gates (degradation and parent mass fraction)?
Degradation product limits
Two degradation thresholds appear:
- < 5% compound degradation products
- Appears in independent claims (Claims 1, 2, 7)
- < 2.5% degradation products (by weight)
- Composition: Claim 3
- Method: Claim 10
The tighter limit is limited to certain parent compounds in the dependent claim text (Claim 3 and Claim 10 each list a subset).
Parent compound mass fraction
Two parent fraction gates appear:
- At least 90% by weight of a specified group of parent drugs
- Composition: Claim 4
- Method: Claim 11
- At least 97% by weight of a specified group of parent drugs
- Composition: Claim 6
- Method: Claim 13
These gates operate as claim narrowing: the independent claims allow “any” amount consistent with “< 5% degradation,” but the dependent claims push towards near-purity of the parent compound.
What are the quantified aerosol size gates (MMAD)?
Two size thresholds appear:
- MMAD < 3 microns
- Independent claims (Claims 1, 2, 7)
- MMAD < 2 microns
- Composition: Claim 5
- Method: Claim 12
- And combined with the parent purity threshold in Claims 6 and 13.
Practical claim meaning
- MMAD < 3 microns defines the basic protected aerosol performance.
- MMAD < 2 microns is a narrower protected performance band.
- Any design-around that increases MMAD above 3 microns or removes the condensation mechanism is outside the claim’s explicit size/performance definitions.
What additional structural or operational limitations appear in dependent method claims?
Dependent method claims add equipment/procedure specificity:
Aerosol formation rate
- Claim 8: aerosol particles are formed at a rate of > 0.5 mg/sec
This is a process throughput limitation. It can matter for infringement if a court ties infringement to the claimed rate, not just the aerosol attributes.
Heating a coating on a metal-foil-textured support
- Claim 9: volatilizing includes heating a coating containing the antipsychotic formed on a solid support with surface texture of a metal foil.
This is a materials/geometry limitation:
- It is not just “heating a compound.”
- It requires the compound to be in a coating layer on a specific type of textured support described as “surface texture of a metal foil.”
This dependent limitation can be a strong differentiator if competitors use different substrate textures, different deposition methods, or different containment architectures (e.g., nozzle-fed solutions, melt films without foil-like texture, or different support surfaces).
How broad is the claim set for “composition” vs “method”?
Composition coverage
- Claims 1-6 protect the aerosol composition defined by:
- formation mechanism (volatilize then condense)
- degradation limit
- MMAD limit
- optional parent purity and tighter MMAD/degradation via dependent claims
A key structural point: the composition claims do not require the substrate type or the rate of formation. They require the aerosol product attributes. That tends to provide broader protection across embodiments that can demonstrate the same aerosol characteristics.
Method coverage
- Claims 7-13 tie the aerosol quality to a specific production procedure:
- pass air through heated vapor during volatilization (Claim 7)
- optionally include throughput (Claim 8) and coating-on-metal-foil texture (Claim 9)
- the remaining dependent claims focus on degradation and parent fraction thresholds, and tighter MMAD
In practice, method claims can be easier to design around if the competitor changes the process mechanics (e.g., uses different air handling so air is not “passed through the heated vapor during volatilizing,” or uses alternative aerosol generation not based on condensation of heated vapor under the claimed conditions).
What does the claim language imply for enforceability and infringement risk?
The “condensation aerosol” mechanism is central
Both composition and method claims require condensation aerosol formation from volatilized heated vapor. If an accused system produces aerosols by atomization of solutions or suspensions (rather than vapor condensation), it may fall outside the literal scope.
Degradation and MMAD are hard numerical gates
The claims specify:
- < 5% degradation products
- MMAD < 3 microns
and narrower:
- < 2.5% degradation
- MMAD < 2 microns
- parent fraction thresholds ≥ 90% and ≥ 97%
These are measurable constraints. If a competitor’s product produces higher degradation or larger MMAD, infringement could be avoided by meeting the different measured specifications.
Dependent process specifics reduce overlap
Claim 9’s “coating on a solid support having surface texture of a metal foil” is a narrower process detail. Many condensation aerosol implementations may use different deposition targets, surfaces, or feed formats. That narrows the subset of method embodiments that match Claim 9.
United States patent landscape: how this patent positions within antipsychotic inhalation/aerosol IP
Given only the claims provided here, the US landscape analysis below is structured around what other patents in this space typically protect, and how 6,716,416’s specific claim hooks map onto those likely claim territories. This patent’s IP profile is defined by a three-dimensional matrix:
- Drug identity (a basket of antipsychotics)
- Particle engineering (MMAD < 3 microns, optionally < 2)
- Process/chemistry outcome (degradation products below defined percentages)
Where it is strong
- Product quality-based claims are harder to design around without materially changing formulation and generation conditions.
- Condensation aerosol mechanism differentiates it from nebulizer-based or jet-milled suspension/solution approaches.
- Multiple drug coverage in a single family style increases business utility across branded and generic portfolios, if the same aerosol methodology can be validated for each.
Where it is narrow
- The enforceable scope is limited to aerosols that satisfy the explicit MMAD thresholds and degradation limits.
- It does not claim a generic “any inhalable antipsychotic” approach; it claims an aerosol that meets specified physical and chemical performance criteria.
- Dependent method claims add specificity (foil-textured support, rate), reducing overlap against dissimilar manufacturing approaches.
Key competitive design-around pathways implied by the claim set
This patent’s structure implies three design-around axes:
-
Aerosol formation mechanism
- Use an approach that does not match “volatilizing to form heated vapor and condensing heated vapor” into “condensation aerosol particles.”
-
Measured aerosol size
- Increase MMAD to ≥ 3 microns (for independent claim avoidance) or ≥ 2 microns (to avoid dependent narrower bands).
-
Measured degradation
- Engineer conditions so the aerosol particles do not have < 5% degradation products (or < 2.5% for tighter dependent claims).
A secondary axis for method claims:
-
Air handling
- Avoid “passing air through the heated vapor during said volatilizing” as the core step.
-
Feed format
- Avoid a “coating” on “surface texture of a metal foil” if targeting Claim 9 overlap.
Business implications for R&D and licensing
What to validate early
To assess infringement risk or freedom-to-operate, the measurable compliance points are:
- MMAD at the specified threshold (3 microns and 2 microns)
- degradation product percentage in the aerosol particles
- parent fraction by weight in the particles
- confirmation that aerosol formation uses vapor condensation
- for method claims: whether air passes through the heated vapor during volatilizing
- for Claim 9: whether the feed is a coating on a metal-foil-textured solid support
Where licensing leverage exists
If a platform company can demonstrate condensation-aerosol production with:
- MMAD below 3 microns (or below 2)
- degradation below 5% (or below 2.5)
then the platform can cover multiple antipsychotics in one technology base, aligning directly with the claim basket in Claims 2 and 7.
Key Takeaways
- US 6,716,416 protects condensation aerosol delivery of multiple antipsychotic drugs with hard numerical gates: degradation < 5% and MMAD < 3 microns.
- Dependent scope tightens performance to degradation < 2.5%, parent drug mass fraction ≥ 90% or ≥ 97%, and MMAD < 2 microns.
- Method claims add process specificity: passing air through heated vapor during volatilization, with further narrowing via > 0.5 mg/sec formation rate and heating a coating on a metal-foil-textured support.
- The enforceable risk concentrates on products/processes that meet the condensation mechanism plus the measured size and degradation thresholds.
FAQs
1) Does the patent require the aerosol to have MMAD below 3 microns?
Yes. The independent composition and method claims require MMAD < 3 microns (Claims 1, 2, 7), with narrower dependent claims requiring MMAD < 2 microns (Claims 5, 12, plus the associated purity claims).
2) What is the maximum allowed degradation products in the broadest claims?
The independent claims require less than 5% compound degradation products (Claims 1, 2, 7). Dependent claims tighten this to less than 2.5% by weight (Claims 3, 10).
3) Which antipsychotics are explicitly listed?
The patent explicitly lists a basket including olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine, and fluphenazine across the main dependent lists (Claims 2 and 7 and their dependent subsets).
4) Is a “metal foil” mentioned only in method claims?
Yes. The “coating on a solid support having the surface texture of a metal foil” limitation appears in Claim 9 as part of the method scope.
5) Can competitors design around by changing the production throughput?
Only if the claimed throughput limitation is at issue. Claim 8 adds > 0.5 mg/sec formation rate, but this is a dependent method feature; the broader infringement analysis depends on meeting the independent claim gates (condensation mechanism, degradation, MMAD).
References
No sources were provided beyond the claim text.
